secwatch.observer — SEC 8-K summary
======================================

Issuer:     Peak Bio, Inc. (—)
CIK:        0001834645
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-127099
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.02, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Peak Bio completes merger with Akari; exchange ratio 0.2935, 48.4% ownership
----------------------------------------------------------------------------

- Each Peak Bio share converted into 0.2935 Akari ADS; Peak stockholders own ~48.4% of combined company.
- Outstanding convertible notes with $8.4M principal converted into 19.4M Peak Bio shares pre-merger.
- Concurrent private placement of 1.71M Akari ADS and warrants raises $3.2M gross proceeds.
- All prior directors resigned; Samir R. Patel appointed President and Secretary post-merger.
- Peak Bio becomes wholly-owned subsidiary of Akari; charter and bylaws amended.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/0000950170-24-127099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/pkbo-20241114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-127099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer